460 related articles for article (PubMed ID: 20920894)
1. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
2. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
Brain Res; 2011 Sep; 1412():44-54. PubMed ID: 21813113
[TBL] [Abstract][Full Text] [Related]
3. Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury.
Hama A; Sagen J
Exp Neurol; 2007 Mar; 204(1):454-7. PubMed ID: 17045264
[TBL] [Abstract][Full Text] [Related]
4. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
5. Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
J Rehabil Res Dev; 2009; 46(1):135-43. PubMed ID: 19533526
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms.
Johanek LM; Heitmiller DR; Turner M; Nader N; Hodges J; Simone DA
Pain; 2001 Sep; 93(3):303-315. PubMed ID: 11514089
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.
Lever IJ; Pheby TM; Rice AS
Br J Pharmacol; 2007 May; 151(2):292-302. PubMed ID: 17375083
[TBL] [Abstract][Full Text] [Related]
8. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
Brownjohn PW; Ashton JC
Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
[TBL] [Abstract][Full Text] [Related]
9. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.
Liu C; Walker JM
J Neurophysiol; 2006 Dec; 96(6):2984-94. PubMed ID: 16943316
[TBL] [Abstract][Full Text] [Related]
10. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice.
Ikeda H; Ikegami M; Kai M; Ohsawa M; Kamei J
Neuroscience; 2013 Oct; 250():446-54. PubMed ID: 23892011
[TBL] [Abstract][Full Text] [Related]
11. Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.
Zhu CZ; Mikusa JP; Fan Y; Hollingsworth PR; Pai M; Chandran P; Daza AV; Yao BB; Dart MJ; Meyer MD; Decker MW; Hsieh GC; Honore P
Br J Pharmacol; 2009 Jun; 157(4):645-55. PubMed ID: 19371344
[TBL] [Abstract][Full Text] [Related]
12. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
Liang YC; Huang CC; Hsu KS
Neuropharmacology; 2007 Jul; 53(1):169-77. PubMed ID: 17572451
[TBL] [Abstract][Full Text] [Related]
13. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
Bilir KA; Anli G; Ozkan E; Gunduz O; Ulugol A
Clin Exp Dermatol; 2018 Jul; 43(5):553-558. PubMed ID: 29424035
[TBL] [Abstract][Full Text] [Related]
14. Topical cannabinoid antinociception: synergy with spinal sites.
Dogrul A; Gul H; Akar A; Yildiz O; Bilgin F; Guzeldemir E
Pain; 2003 Sep; 105(1-2):11-6. PubMed ID: 14499415
[TBL] [Abstract][Full Text] [Related]
15. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
16. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats.
Pascual D; Goicoechea C; Suardíaz M; Martín MI
Pain; 2005 Nov; 118(1-2):23-34. PubMed ID: 16213089
[TBL] [Abstract][Full Text] [Related]
17. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.
Bridges D; Ahmad K; Rice AS
Br J Pharmacol; 2001 Jun; 133(4):586-94. PubMed ID: 11399676
[TBL] [Abstract][Full Text] [Related]
18. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.
Naidu PS; Kinsey SG; Guo TL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2010 Jul; 334(1):182-90. PubMed ID: 20375198
[TBL] [Abstract][Full Text] [Related]
19. Administration of ONO-2506 suppresses neuropathic pain after spinal cord injury by inhibition of astrocytic activation.
Ishiguro H; Kaito T; Hashimoto K; Kushioka J; Okada R; Tsukazaki H; Kodama J; Bal Z; Ukon Y; Takenaka S; Makino T; Sakai Y; Yoshikawa H
Spine J; 2019 Aug; 19(8):1434-1442. PubMed ID: 30974239
[TBL] [Abstract][Full Text] [Related]
20. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms.
Potenzieri C; Harding-Rose C; Simone DA
Brain Res; 2008 Jun; 1215():69-75. PubMed ID: 18486111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
